AAP
DMAC icon

Arax Advisory Partners’s DiaMedica Therapeutics DMAC Stock Holding History

Arax Advisory Partners’s Portfolio DMAC Stock Details DMAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$56 Buy
+8
New +$49 ﹤0.01% 5159
2025
Q4 		– Sell
-32
Closed -$219 – 4197
2025
Q3 		$219 Buy
+32
New +$174 ﹤0.01% 3442

Other funds holding DMAC

CLG
Cooperman Leon G $3.55B AUM 41.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Arax Advisory Partners's DMAC Position: Q2 2026 in Review

Arax Advisory Partners opened a new position in DiaMedica Therapeutics (DMAC) in Q2 2026: 8 shares worth $56. The stake represents ﹤0.01% of the portfolio and ranks #5159 among its holdings. This is a return to the name: Arax Advisory Partners previously reported a position in DMAC as recently as Q3 2025.

Arax Advisory Partners first reported a position in DMAC in Q3 2025 and has held it in 2 quarters since. The position peaked at $219 in Q3 2025. 89 funds tracked by Wall St. Rank hold DMAC as of Q2 2026.

  • Arax Advisory Partners held 8 shares of DiaMedica Therapeutics worth $56 as of Q2 2026.
  • DiaMedica Therapeutics was a new Arax Advisory Partners position in Q2 2026.
  • DiaMedica Therapeutics made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #5159 holding.
  • Arax Advisory Partners first reported a position in DiaMedica Therapeutics in Q3 2025 and has held it in 2 quarters since.
  • Arax Advisory Partners's DiaMedica Therapeutics position peaked at $219 in Q3 2025.
  • 89 funds tracked by Wall St. Rank held DiaMedica Therapeutics as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.